|
|
Beheersen van bloedingsrisico’s:Wat is de balans?
|
|
|
|
What is the balance?
|
|
|
|
TRITON – TIMI 38
|
|
|
|
Summary of ACS Treatments
|
|
|
|
Antiplatelet therapy: efficacy vs safety
|
|
|
|
Thrombus composition in STEMI
|
|
|
|
|
|
N Engl J Med 2006;354;1464-1476
|
|
|
|
|
Major Bleeding Endpoint
|
|
|
|
Impact of MI and Major Bleeding
|
|
|
|
|
|
Three-Year All-Cause Mortality
|
|
|
|
|
|
Sources and Incidence of Bleeding
|
|
|
|
Relative Risk of 1-Year Mortality
|
|
|
|
Impact of Randomized Antithrombotic Therapy
|
|
|
|
Impact of Randomized Antithrombotic Therapy
|
|
|
|
Time from CABG to any death
|
|
|
|
Bleeding from time of CABG
|
|
|
|
Transfusions from time of CABG
|
|
|
|
Conclusions Bleeding in ACS
|
|
|
|
Conclusions Bleeding in ACS
|
|
|
|
Risk factors for anticoagulant-related bleeding
|
|
|
|
Higher stroke risk = higher bleeding risk
|
|
|
|
HAS-BLED bleeding risk score
|
|
|
|
The HAS-BLED bleeding risk score
|
|
|
|
Higher bleeding rates seen with high HASBLED score
|
|
|
|
Predictive value of contemporary bleeding risk stratification schemes
|
|
|
|
net clinical benefit (NCB) of VKA treatment
|
|
|
|
Stroke Prevention in AF
|
|
|
|
|
|
|
|
Major Bleeding ISTH definition
|
|
|
|
Conclusions Bleeding in AF
|
|
07_F.Verheugt (PPTX 5,6MB)
Deel deze pagina met collega's en vrienden: